Phase 3
Completed N=508
A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)
Source: ClinicalTrials.gov NCT02059161 ↗Enrolled (actual)
508
Serious AEs
10.6%
Results posted
Mar 2017
Primary outcomePrimary: Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24 — -0.62; -0.66 Percent
◆ Published Evidence
Emerging
9citations · ~1 / year
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
Summary
The purpose of this study is to compare the safety and efficacy of MK-1293 to Lantus™ in participants with T1DM. The primary hypothesis is that after 24 weeks, the mean change in hemoglobin A1c (A1C) from baseline is non-inferior in participants treated with MK-1293 compared with participants treated with Lantus™.
Linked Publications
-
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24 |
-0.62; -0.66 | — |
| PRIMARY Percentage of Participants With Any Confirmed Positive Anti-insulin Antibody (AIA) at Any Time Up Through Week 24 |
70.1; 74.0 | — |
| PRIMARY Percentage of Participants With Negative AIA at Baseline Who Develop Confirmed Positive AIA at Any Time Up Through Week 24 |
32.7; 35.7 | — |
| PRIMARY Change From Baseline in AIA Titer After 24 Weeks of Treatment |
0.4; 0.3 | — |
| PRIMARY Percentage of Participants Who Develop Insulin Neutralizing Antibodies Up Through Week 24 |
3.9; 5.3 | — |
| SECONDARY Change From Baseline in A1C at Week 52 |
-0.35; -0.33 | — |
| SECONDARY Total Insulin Dose at Week 24 |
58.74; 60.51 | — |
| SECONDARY Total Insulin Dose Per Kilogram (kg) of Body Weight (Unit/kg) at Week 24 |
0.75; 0.77 | — |
| SECONDARY Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 |
-16.8; -26.4 | — |
| SECONDARY Percentage of Participants With Confirmed Positive AIA Up Through Week 52 |
73.4; 75.6 | — |
| SECONDARY Percentage of Participants With Negative AIA at Baseline Who Develop Confirmed Positive AIA at Any Time Up Through Week 52 |
40.6; 39.8 | — |
| SECONDARY Change From Baseline in AIA Titer After 52 Weeks of Treatment |
-1.6; 0.1 | — |
| SECONDARY Total Insulin Dose at Week 52 |
59.16; 60.93 | — |
| SECONDARY Total Insulin Dose Per Kilogram (kg) of Body Weight (Unit/kg) at Week 52 |
0.75; 0.77 | — |
| SECONDARY Change From Baseline in FPG at Week 52 |
-17.9; -12.5 | — |
| SECONDARY Percentage of Participants Who Develop Insulin Neutralizing Antibodies Up Through Week 52 |
4.7; 6.9 | — |
| SECONDARY Change From Baseline in 7-point Self-monitored Blood Glucose (SMBG) at Week 24 |
-4.9; -4.6 | — |
| SECONDARY Change From Baseline in 7-point SMBG at Week 52 |
-12.0; -4.0 | — |
| SECONDARY Percentage of Participants Attaining A1C Glycemic Goals of <7% and <6.5% After 24 Weeks of Treatment. |
37.0; 37.7; 20.5; 21.6 | — |
| SECONDARY Percentage of Participants Attaining A1C Glycemic Goals of <7% and <6.5% After 52 Weeks of Treatment. |
31.0; 30.8; 14.2; 18.6 | — |
| SECONDARY Basal Insulin Dose at Week 52 |
36.08; 36.51 | — |
| SECONDARY Basal Insulin Dose Per kg of Body Weight at Week 52 |
0.46; 0.47 | — |
| SECONDARY Bolus Insulin Dose at Week 52 |
22.15; 23.65 | — |
| SECONDARY Bolus Insulin Dose Per kg of Body Weight at Week 52 |
0.28; 0.30 | — |
| SECONDARY Basal Insulin Dose at Week 24 |
36.33; 37.07 | — |
| SECONDARY Basal Insulin Dose Per kg of Body Weight at Week 24 |
0.46; 0.48 | — |
| SECONDARY Bolus Insulin Dose at Week 24 |
21.65; 22.91 | — |
| SECONDARY Bolus Insulin Dose Per kg of Body Weight at Week 24 |
0.28; 0.29 | — |
Eligibility Criteria
Inclusion Criteria
- T1DM For at least 1 year
- is currently using or has been using prandial insulin for at least 4 weeks. Participants taking any type of basal insulin should require a total daily dose of >=10 units/day. For participants currently taking pre-mixed insulin, the basal insulin component should be equivalent to a total daily dose of >=10 units/day.
- is male, or is female who is not of reproductive potential or if of reproductive potential agrees to remain abstinent or use (or have their partner use) an acceptable method of birth control during the study and for 14 days after the last dose of study medication
Exclusion Criteria
- has had 1 or more severe hypoglycemic episodes associated with hypoglycemic seizure or loss of consciousness within the past 6 months
- history of ketoacidosis in the last 6 months
- participant, as assessed by the investigator, is not appropriate for or does not agree to target a fasting glucose of 70-100 mg/dL [3.9 -5.6 mmol/L].
- history of intolerance or hypersensitivity to Lantus™ or contraindication to Lantus™ or one of its excipients
- used a formulation of insulin glargine other than Lantus™
- has received injectable incretin-based therapy within the past 8 weeks
- on a weight loss program and not in the maintenance phase, or has started a weight loss medication within the past 8 weeks
- has undergone bariatric surgery within the past 12 months
- is likely to require treatment for 2 or more consecutive weeks or repeated courses of corticosteroids (note: inhaled, nasal, and topical corticosteroids are permitted)
- has undergone a surgical procedure within the past 4 weeks or has planned major surgery during the study
- has new or worsening signs or symptoms of coronary heart disease or congestive heart failure within the past 3 months, or has any following disorders within the past 3 months: acute coronary syndrome, coronary artery intervention, stroke or transient ischemic neurological disorder
- has severe peripheral vascular disease
- has high blood pressure
- has chronic myopathy, or a progressive neurological or neuromuscular disorder
- has active nephropathy
- history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease
- has human immunodeficiency virus (HIV)
- has a hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)
- history of malignancy in the past 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
- history of melanoma, leukemia, lymphoma, or renal cell carcinoma
- is currently being treated for hyperthyroidism or has been on a stable dose of thyroid hormone replacement therapy for 300 mL within the past 8 weeks or intends to donate blood products during the study
- has poor mental function or works the night shift
Data sourced from ClinicalTrials.gov (NCT02059161) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.